La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Ergomed Croissance future

Future contrôle des critères 3/6

Ergomed devrait augmenter ses bénéfices et son chiffre d'affaires de 14.2% et de 8.8% par an respectivement. Le BPA devrait croître de de 13.7% par an. Le rendement des capitaux propres devrait être 19.3% dans 3 ans.

Informations clés

14.2%

Taux de croissance des bénéfices

13.7%

Taux de croissance du BPA

Life Sciences croissance des bénéfices	25.9%
Taux de croissance des recettes	8.8%
Rendement futur des capitaux propres	19.3%
Couverture par les analystes	Good
Dernière mise à jour	13 Nov 2023

Mises à jour récentes de la croissance future

Recent updates

If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today

Feb 22

Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Jan 18

Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price

Dec 13

We Think Ergomed's (LON:ERGO) Statutory Profit Might Understate Its Earnings Potential

Nov 23

Prévisions de croissance des bénéfices et des revenus

AIM:ERGO - Estimations futures des analystes et données financières antérieures (GBP Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	199	27	29	33	7
12/31/2024	180	23	26	30	7
12/31/2023	161	20	23	26	7
6/30/2023	152	15	17	19	N/A
3/31/2023	149	15	15	17	N/A
12/31/2022	145	15	13	15	N/A
9/30/2022	139	14	14	15	N/A
6/30/2022	132	13	15	16	N/A
3/31/2022	126	13	16	17	N/A
12/31/2021	119	13	18	19	N/A
9/30/2021	110	12	18	19	N/A
6/30/2021	102	12	17	18	N/A
3/31/2021	94	11	17	18	N/A
12/31/2020	86	10	17	18	N/A
9/30/2020	80	8	16	17	N/A
6/30/2020	73	6	16	17	N/A
3/31/2020	71	6	13	14	N/A
12/31/2019	68	6	11	12	N/A
9/30/2019	66	1	7	8	N/A
6/30/2019	64	-3	2	4	N/A
3/31/2019	59	-6	1	3	N/A
12/31/2018	54	-9	1	2	N/A
9/30/2018	54	-8	1	2	N/A
6/30/2018	54	-8	1	3	N/A
3/31/2018	51	-6	0	1	N/A
12/31/2017	48	-5	-1	0	N/A
9/30/2017	42	-2	-2	-1	N/A
6/30/2017	36	0	-4	-2	N/A
3/31/2017	33	0	N/A	-2	N/A
12/31/2016	29	0	N/A	-2	N/A
9/30/2016	31	1	N/A	-2	N/A
6/30/2016	28	1	N/A	-2	N/A
3/31/2016	29	1	N/A	-1	N/A
12/31/2015	30	2	N/A	0	N/A
9/30/2015	29	1	N/A	1	N/A
6/30/2015	28	1	N/A	2	N/A
3/31/2015	24	1	N/A	1	N/A
12/31/2014	21	1	N/A	1	N/A
9/30/2014	19	1	N/A	0	N/A
6/30/2014	16	1	N/A	-1	N/A
3/31/2014	16	1	N/A	0	N/A
12/31/2013	15	2	N/A	1	N/A
12/31/2012	15	0	N/A	1	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ERGO ( 14.2% par an) est supérieure au taux d'épargne ( 1.5% ).

Bénéfices vs marché: Les bénéfices de ERGO ( 14.2% par an) devraient croître plus rapidement que le marché UK ( 14.3% par an).

Croissance élevée des bénéfices: Les bénéfices de ERGO devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ERGO ( 8.8% par an) devrait croître plus rapidement que le marché UK ( 3.7% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ERGO ( 8.8% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de ERGO devrait être faible dans 3 ans ( 19.3 %).

Ergomed Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Consensus EPS estimates increase by 11%

Consensus forecasts updated

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

Price target increased to UK£13.65

Price target increased to UK£12.70

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Now 20% undervalued after recent price drop

Is It Time To Consider Buying Ergomed plc (LON:ERGO)?

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ergomed plc, Annual General Meeting, Jun 22, 2023

At UK£9.74, Is Ergomed plc (LON:ERGO) Worth Looking At Closely?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Ergomed plc (LON:ERGO) Shares Could Be 21% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Should You Be Adding Ergomed (LON:ERGO) To Your Watchlist Today?

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings: EPS misses analyst expectations

Ergomed plc, Annual General Meeting, Jun 10, 2022

Consensus EPS estimates increase by 11%

Consensus forecasts updated

Less than half of directors are independent

Now 21% undervalued

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Full year 2021 earnings: EPS misses analyst expectations

Does Ergomed (LON:ERGO) Deserve A Spot On Your Watchlist?

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Ergomed (LON:ERGO) Passed With Ease

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Calculating The Intrinsic Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Ergomed (LON:ERGO) Before It's Too Late

Getting In Cheap On Ergomed plc (LON:ERGO) Might Be Difficult

Ergomed plc (LON:ERGO) Shares Could Be 31% Above Their Intrinsic Value Estimate

Price target increased to UK£13.65

Non-Executive Director has left the company

Investor sentiment improved over the past week

Do Ergomed's (LON:ERGO) Earnings Warrant Your Attention?

Full year 2020 earnings released

Price target increased to UK£12.70

If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today

New 90-day high: UK£12.45

Ergomed plc to Report Fiscal Year 2020 Results on Mar 23, 2021

Price target raised to UK£11.85

Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

New 90-day high: UK£10.55

Ergomed plc (AIM:ERGO) acquired MedSource Consulting Inc. for $25 million.

Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price

New 90-day high: UK£9.50